AF ablation is a waste of time and money

Slides:



Advertisements
Similar presentations
Maenne Okunola Pharm D. Candidate: University of Georgia June 2012 Preceptor: Dr. Ali Rahimi.
Advertisements

Egyptian Perspective On Prediabetes & Diabetes
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.
5.2 Systems of Linear Equations in Three Variables
Practical Rate and Rhythm Management of Atrial Fibrillation
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Multiplication Facts Review. 6 x 4 = 24 5 x 5 = 25.
0 - 0.
2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt ShapesPatterns Counting Number.
MULT. INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
$100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400.
AF ablation with 3D mapping: our technique and results
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Managing anticoagulation in atrial fibrillation Dr Katy Rice June 2011.
1 GRASP-AF Audit - Intro 8 th July 2010 Mark Gregory.
AF ablation: A single operator’s experience over 3 years (2007 – 2009) Barker D, Patwala A, Damm E, Hall M, Snowdon R, Gupta D Liverpool Heart and Chest.
Surgical Risk Dr Chris Snowden MD FRCA Consultant Anaesthetist
Figure Essential Cell Biology (© Garland Science 2010)
Bariatric Failures Paolo Gentileschi Bariatric Surgery Unit University of Rome Tor Vergata.
EXAMPLE 3 Use synthetic division
Practice Skip Counting 8.
{ Cardioversion turns 50 Seth Bilazarian MD Private practice theheart.org.
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
How to do a Roof Line and Prove Block Dhiraj Gupta Liverpool Heart and Chest Hospital.
Nancy M Allen LaPointe, Yuliya Lokhnygina, Gillian Sanders, Eric Peterson, and Sana Al- Khatib Is Selection of Antiarrhythmic Drugs for Atrial Fibrillation.
Atrial Fibrillation Update 2012 Dr C Seifer Section of Cardiology St Boniface Hospital.
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
Atrial Fibrillation. Statistics 1.5% of people over 65 have AF 1.5% of people over 65 have AF 5x increased risk of stroke 5x increased risk of stroke.
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.
Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.
Audit of ablation procedures for AF Barts and The London.
Samer Nasr, M.D. Mount Lebanon Hospital..  Lone atrial fibrillation:  Younger than 60 years old.  No clinical or echo evidence of cardiopulmonary.
Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Atrial Fibrillation Rate or rhythm control? Who should be anticoagulated? Other treatment strategies.
Muhammad S Ajmal MBBS Aravind Herle MD FACC. Atrial fibrillation (AF) A supraventricular tachyarrhythmia characterized by uncoordinated atrial activation.
Background, recognition and differentials. By Dr L Axten.
Overview of the AFFIRM Study
AF: Catheter Ablation Isolation of the 4 pulmonary veins Linear lesions to create additional lines of block 1.
Barts and The London NHS Trust NHS Barts and The London NHS Trust NHS AF ablations at SBH August 2008 – August 2009 Patients undergoing first ablation.
EP Show – December 2002 AFFIRM The EP Show: AFFIRM Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
Atrial Fibrillation Ablation: Who and Why ?
DIFFICULT DECISIONS IN HEALTH CARE Presentation to OJHOSC Dr Ljuba Stirzaker Oxfordshire Primary Care Trust 13 March 2008 ITEM JHO8(a) JHO3.MAR1308R03.ppt.
Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
1 AF: Issues with Anticoagulation AFL: Anticoagulation like AF When undergoing procedures with risk for bleeding: May DC warfarin for up to one week without.
ASCEND-HF Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Duke Heart Failure Research Pager:
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
THE MANAGEMENT OF ACUTE AF. DR TRENT LIPP ROYAL BRISBANE AND WOMEN’S AND LOGAN HOSPITALS GETTING AGGRESSIVE WITH AF.
HOPE: Heart Outcomes Prevention Evaluation study
Volume 14, Issue 6, Pages (June 2017)
AF ablation with 3D mapping: our technique and results
Figure 4 BMI and mortality in patients with heart failure
Community Health Pearl:
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
Volume 14, Issue 6, Pages (June 2017)
Iron Deficiency in Heart Failure
Left-Sided Surgical Ablation for Patients With Atrial Fibrillation Who Are Undergoing Concomitant Cardiac Surgical Procedures  Niv Ad, MD, Sari D. Holmes,
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management  Anne M. Gillis, MD, FRCPC, Atul Verma, MD, FRCPC, Mario.
Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.
Volume 14, Issue 6, Pages (June 2017)
Presentation transcript:

AF ablation is a waste of time and money Dr Dhiraj Gupta MRCP MD DM Liverpool Heart and Chest Hospital

AF ablation is a waste of time and money: (you must be joking!) Dr Dhiraj Gupta MRCP MD DM Liverpool Heart and Chest Hospital

A recap of what we’ve learnt this morning….

AF kills you (slowly)….

AF makes you miserable….

2.4% of the total NHS budget AF costs megabucks…. 2.4% of the total NHS budget

Conventional treatments limited efficacy Drugs only work in 1 in 3 patients

Not only are drugs potentially ineffective but….. They often cause unacceptable side effects Discontinuation rates due to Adverse Effects: CTAF: 18% Amio, 11% Sotalol AFFIRM: 12% Amio, 11% Sotalol, 28% Flecainide They may increase mortality SPAF: esp. in heart failure AFFIRM: AAD associated with  mortality (p=0.0005)

Dronedarone isn’t the answer…. Mild antiarrhythmic action AF recurrence at 1 year: 64% vs 75% for Placebo << Amiodarone (free from AF at 6 mo: 37% vs 58%) Increased mortality in Heart Failure (ANDROMEDA) Only approved by the NICE with reservations

….and neither is cardioversion

Finally, a cure is in sight!...... Culprit: triggers in pulmonary veins

Treatment: Pulmonary Vein Isolation

Current success rates 80% The procedure works….. Current success rates 80%

in long standing persistent AF too.. Redo AAD therapy Results Complications Haissaguerre JCE 2005 60 1/2 Stopped at ablation 95% at 11 months 2 Tamponades Oral NEJM 2006 77 1/3 Amio 6/52 pre & 3/12 post 77% at 1 year Postch Circ 2008 88 81% at 20 months 1 TIA Lo JCE 2009 87 1/4 AAD for 2/12 post 79% at 21 months 1 Tamponade

It’s clearly better than drug therapy

AF ablation has evolved rapidly… Success rates have doubled Paroxysmal AF: 40-50% to 80-90% Persistent AF: 30-40% to 70-80% Procedure times have halved From 4-6 hours to 2-3 hours Complication rates have halved: 4% to 2%

Current technology has improved accuracy

The last thing we now need is a party pooper!

Drugs Ablation 30% efficacy 80% chance of cure Life long suffering One-stop solution

If you always do what you always did…you’ll always get what you’ve always got

Yes, AF ablation costs money… 100,000 AF cases a year Median 1.5 procedures £4000 per ablation Total cost: half a billion pounds

But where would you rather spend this money? ? Iraq War: £ 4.5 billion (Mar 2006) ? Olympics: £9.8 billion ? NHS IT project: £15 billion ? Bank Bailout £850 billion

Upfront costs outweighed by subsequent savings… Costs of recurrent hospital admissions Electrical cardioversions Absences from work Costs of lifelong drug therapy Regular INR tests Decreased risk of the serious AF sequalae Stroke Heart Failure

Measures to make ablation more cost effective 1. Careful patient selection: ablation not offered Very long standing Persistent AF (>3 years) Very large LA (>5.5 cm) Morbid Obesity (BMI >40) Age >80 years Significant co-morbidity

Measures to make ablation more cost effective 2. Individualised ablation strategy: Improve single procedure success rates Accepted for oral presentation at Cardiostim, Nice June 16-18, 2010

Finally... What would you want?!